4.7 Article

Diabetes and Cancer A consensus report

期刊

DIABETES CARE
卷 33, 期 7, 页码 1674-1685

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dc10-0666

关键词

-

资金

  1. Amylin Pharmaceuticals, Inc.
  2. Lilly USA
  3. Merck Company, Inc.
  4. Novo Nordisk A/S
  5. Sanofi-aventis Groupe
  6. Amylin
  7. Bayer Diabetes Care
  8. Eli Lilly
  9. Mannkind
  10. Medtronic
  11. National Institutes of Health (NIH)
  12. Novo Nordisk
  13. ResMed
  14. Life Scan
  15. American Diabetes Association

向作者/读者索取更多资源

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据